CAR NK ther­a­py looks durable in a small tri­al, giv­ing in­sight in­to large Take­da study

An “off-the-shelf” cell ther­a­py en­gi­neered us­ing nat­ur­al killer cells re­sult­ed in last­ing re­spons­es in a small clin­i­cal tri­al for cer­tain lym­phomas and leukemia, ac­cord­ing to new study re­sults pub­lished Thurs­day.

The Na­ture Med­i­cine study, con­duct­ed by Katy Rez­vani’s lab at MD An­der­son Can­cer Cen­ter, al­so showed the im­por­tance of se­lect­ing on­ly cer­tain donor cells to use in en­gi­neer­ing these ther­a­pies. The idea be­hind nat­ur­al killer, or NK, cell ther­a­pies is that they can pro­vide a less cost­ly and more read­i­ly avail­able op­tion for can­cer pa­tients, un­like cur­rent CAR-T cell ther­a­pies, which are en­gi­neered in­di­vid­u­al­ly for each pa­tient from their own cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER